Response to Capmatinib in a MET Fusion-positive Cholangiocarcinoma.
Oncologist
; 28(1): 80-83, 2023 01 18.
Article
em En
| MEDLINE
| ID: mdl-36434677
ABSTRACT
Cholangiocarcinoma is the second most common liver cancer after hepatocellular carcinoma. In case of metastatic or unresectable disease, the recommended first-line treatment is gemcitabine-based doublet, most commonly gemcitabine and cisplatin. There is no standard treatment for further lines. MET fusions are rare alterations described in many cancers. The efficacy of specific MET inhibitors is poorly studied. We present the case of a patient with chemotherapy-refractory metastatic cholangiocarcinoma harboring a CAPZA-2-MET fusion along with MET amplification who dramatically responded to capmatinib, a specific MET tyrosine kinase inhibitor.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias dos Ductos Biliares
/
Colangiocarcinoma
/
Neoplasias Hepáticas
Limite:
Humans
Idioma:
En
Revista:
Oncologist
Ano de publicação:
2023
Tipo de documento:
Article